DOCS TALK SHOP
Eavesdrop as Dawn Lemanne, MD, and Deborah Gordon, MD discuss their difficult cases and the hard decisions they make behind the closed door of the exam room, when the textbooks and research protocols fall short. They also share with each other which longevity protocols, hormones, mTOR inhibitors, senolytics, extreme diets and fasting, hormesis, cancer prevention, and dementia reversal protocols they prescribe, and which ones they quietly have tried for themselves.
Anything else you want to hear about? Write to us!
Dr Gordon: info@drdeborahmd.com
Dr Lemanne: newsletter@oregonio.com
DOCS TALK SHOP
31. Rewiring Risk: Fixing ADHD Decreases Alzheimers, Social Jet Lag Ups Cancer Risk, and a theoretical strategy to treat prostate cancer
Treat ADHD, lower Alzheimer’s risk?
The episode explores emerging evidence that simply having ADD/ADHD raises lifetime Alzheimer’s risk—yet appropriately treating it in adults, often with low-dose stimulants, seems to push that risk back down. How can the same class of drugs be both feared as “brain-burning” and yet potentially brain-saving—and what does that mean for people already in midlife?
Treating prostate cancer successfully with--testosterone?
Listeners are introduced to a first-in-oncology “directed evolution” case in metastatic prostate cancer, led by Dr. Lemanne’s team, where high-dose testosterone was deliberately used to expand treatment-sensitive cells—and only then was hormone blockade re-introduced. But did this radical, counterintuitive maneuver actually work?
Emotional trauma in youth as a hidden Alzheimer’s driver? Dr. Gordon discusses links between youth emotional trauma to higher rates of Alzheimer’s decades later, even in people who appear to have “moved on.” Is this just correlation, or should early emotional trauma be considered a subtle form of brain injury that can and should be addressed?
Do you go to bed later on weekends, by just 1-2 hours, but make up for it by rising later? If so, you'll want to know that you may be increasing your risk of breast or prostate cancer. This episode explores that research.
Have you heard of the new Alzheimer’s blood tests, that improve as the patient improves, allowing better direction of treatment?
Dr. Gordon walks us through the ATN panel (amyloid-beta, p-tau, neurofilament light), now accessible through routine laboratory tests, along with galectin-3 as a tau-clustering, inflammation-linked marker, and a new infusion drug (TB006) targeting that pathway. But can these numbers really be moved in the right direction with targeted lifestyle and medical interventions—and what happens when they are?
Enjoy this unusual episode!
And write to us. We read every email.
Dawn Lemanne, MD
Oregon Integrative Oncology
Leave no stone unturned.
Deborah Gordon, MD
Northwest Wellness and Memory Center
Building Healthy Brains
